• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>感染症学雑誌 >Respiratory syncytial virus infection
【24h】

Respiratory syncytial virus infection

机译：呼吸道合胞病毒感染

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human respiratory syncytial virus (RSV) is the most common worldwide cause of lower respiratory tract infections (LRI) in infants less than 12 months of age. RSV isolates can be divided into group A and B. In addition, there were many genotypes within each group, and these genotypes have evolved global setting with temporal and geographic clustering. Many cellular genes encoding cytokines and chemokines which are activated by RSV infection has now been focused for the elucidation of pathophysiology of RSV LRI. The prophylaxis against RSV infection by vaccination has been unsuccessful because of its adverse effects. No valuable anti-RSV drugs for clinical use have been yet developed. Therefore RSV LRI has been treated mainly symptomatically. Recently humanized anti-RSV F protein monoclonal antibody was developed and prescribed for prevention in high-risk infants such as premature ones and those with chronic lung and congenital heart diseases. It reduced the incidence of hospitalization significantly.
机译：人类呼吸道合胞病毒（RSV）是全世界12个月以下婴儿下呼吸道感染（LRI）的最常见原因。 RSV分离株可分为A组和B组。此外，每组中都有许多基因型，并且这些基因型随着时间和地理聚类而演变为全球环境。现在已经将许多编码被RSV感染激活的细胞因子和趋化因子的细胞基因用于阐明RSV LRI的病理生理学。由于其不良反应，因此预防接种RSV感染的方法尚未成功。尚未开发出可用于临床的有价值的抗RSV药物。因此，RSV LRI已被主要对症治疗。最近开发了人源化的抗RSV F蛋白单克隆抗体，并已开处方用于预防高危婴儿，如早产儿以及患有慢性肺和先天性心脏病的婴儿。它显着降低了住院率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号